Compare · ARGX vs XTNT
ARGX vs XTNT
Side-by-side comparison of argenx SE (ARGX) and Xtant Medical Holdings Inc. (XTNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and XTNT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 1409.9x XTNT ($44.9M).
- XTNT has been more active in the news (14 items in the past 4 weeks vs 11 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 1 for XTNT).
- Company
- argenx SE
- Xtant Medical Holdings Inc.
- Price
- -
- -
- Market cap
- $63.27B
- $44.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- News (4w)
- 11
- 14
- Recent ratings
- 25
- 1
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Xtant Medical Holdings Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest XTNT
- Director Lipschultz Tyler was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)
- Director Bakewell John K was granted 215,517 shares, increasing direct ownership by 24% to 1,129,633 units (SEC Form 4)
- Director Beeson Jonn R. was granted 215,517 shares, increasing direct ownership by 42% to 733,136 units (SEC Form 4)
- Director Jain Abhinav was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)
- Director Vizirgianakis Stavros G. was granted 323,275 shares, increasing direct ownership by 4% to 7,838,845 units (SEC Form 4)
- Chief Operating Officer Schallenberger Mark A. was granted 450,000 shares and covered exercise/tax liability with 7,070 shares, increasing direct ownership by 67% to 1,106,087 units (SEC Form 4) (withholding obligation)
- CFO and Assistant Secretary Neils Scott C was granted 400,000 shares and covered exercise/tax liability with 28,155 shares, increasing direct ownership by 44% to 1,215,226 units (SEC Form 4) (for withholding tax)
- President and CEO Browne Sean E was granted 550,000 shares and covered exercise/tax liability with 10,605 shares, increasing direct ownership by 21% to 3,114,669 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Xtant Medical Holdings Inc.
- Xtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits